ArticleJCO oncology practice2025

Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab.

Athira Jayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.